Literature DB >> 27932066

Raising the bar on first-line immunotherapy in lung cancer.

Jessica J Lin1, Alice T Shaw2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27932066     DOI： 10.1016/S1470-2045(16)30594-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.

Authors:  Shouheng Lin; Guohua Huang; Lin Cheng; Zhen Li; Yiren Xiao; Qiuhua Deng; Yuchuan Jiang; Baiheng Li; Simiao Lin; Suna Wang; Qiting Wu; Huihui Yao; Su Cao; Yang Li; Pentao Liu; Wei Wei; Duanqing Pei; Yao Yao; Zhesheng Wen; Xuchao Zhang; Yilong Wu; Zhenfeng Zhang; Shuzhong Cui; Xiaofang Sun; Xueming Qian; Peng Li
Journal:  MAbs       Date:  2018-10-02       Impact factor: 5.857

2.  The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer.

Authors:  Long Jiang; Jia Huang; Shanshan Jiang; Wenwen Rong; Yaofeng Shen; Chongwu Li; Yu Tian; Junwei Ning; Xiaoke Chen; Yunhai Yang; Zhengping Ding; Ziming Li; Qingquan Luo
Journal:  Cancer Immunol Immunother       Date:  2021-01-29       Impact factor: 6.968
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.